Adeno-associated virus vectors are able to restore fatty aldehyde dehydrogenase-deficiency. Implications for gene therapy in Sjögren-Larsson syndrome
- 15 April 2005
- journal article
- research article
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 296 (12) , 568-572
Abstract
Sjögren-Larsson Syndrome (SLS) is caused by an autosomal recessive defect in the gene coding for fatty aldehyde dehydrogenase (FALDH), an enzyme necessary for the oxidation of long-chain aliphatic aldehydes to fatty acid as one enzyme of the fatty alcohol:nicotinamide-adenine dinucleotide (NAD+)-oxidoreductase complex (FAO). The impaired activity of FALDH leads to the clinical symptom triad of generalized ichthyosis, mental retardation, and spastic diplegia or tetraplegia. Treatment options are primarily symptomatic. Gene therapy by means of genetic reintroduction of the functional FALDH gene into defective cells has so far not been considered as a therapeutic modality. In order to pursue such an approach for SLS, we constructed a recombinant adeno-associated virus-2 vector containing the human cDNA of functional FALDH and evaluated its capability to restore the enzyme-deficiency in a FALDH-deficient cell line resembling the gene defect of SLS. rAAV-2 transduction of FALDH-deficient cells, usually exhibiting less than 10% of normal FALDH activity, resulted in an increase of FALDH activity within the range of unaffected cells. Moreover, FALDH-transduced cells regained resistance over exposure to long chain aldehydes, which are otherwise toxic to FALDH-deficient cells. These results indicated that rAAV-2 vectors are able to restore FALDH-deficiency in a cell system resembling SLS. The findings give the first support to the concept that gene therapy might be a future option for the treatment of SLS.Keywords
This publication has 16 references indexed in Scilit:
- Recombinant adeno-associated virus type 2-mediated gene transfer into human keratinocytes is influenced by both the ubiquitin/proteasome pathway and epidermal growth factor receptor tyrosine kinaseArchives of Dermatological Research, 2005
- Progress in the Use of Adeno-Associated Viral Vectors for Gene TherapyCells Tissues Organs, 2004
- Sjörgen-Larsson-SyndromDie Dermatologie, 2000
- The Molecular Basis of Sjögren-Larsson Syndrome: Mutation Analysis of the Fatty Aldehyde Dehydrogenase GeneThe American Journal of Human Genetics, 1999
- Efficient gene transfer into human keratinocytes with recombinant adeno-associated virus vectorsGene Therapy, 1999
- Isolation of Animal Cell Mutants Defective in Long-chain Fatty Aldehyde DehydrogenaseJournal of Biological Chemistry, 1997
- Sjögren–Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase geneNature Genetics, 1996
- Sjögren-Larsson syndrome. Deficient activity of the fatty aldehyde dehydrogenase component of fatty alcohol:NAD+ oxidoreductase in cultured fibroblasts.Journal of Clinical Investigation, 1991
- Carrier detection for Sjögren‐Larsson syndromeJournal of Inherited Metabolic Disease, 1991
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI: Journal of the National Cancer Institute, 1990